[Inhibition of ovarian function using a triphasic combination with gestodene].
The author reports the results of a prospective study of 10 women during six months use of an oral contraceptive combination with gestodene. Inhibition of ovarian function is showed by rapidly decreasing serum levels of estradiol and progesterone. Clinical and metabolic tolerance is excellent.
Rozenbaum
H
H
D000328:Adult; D003276:Contraceptives, Oral / Q000008:administration & dosage / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000627:therapeutic use*; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D009652:Norpregnenes / Q000008:administration & dosage / Q000627:therapeutic use*; D010053:Ovary / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; D011374:Progesterone
Inhibition de la fonction ovarienne par une association triphasique au gestodène.